MANNATECH INC (MTEX) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does MANNATECH INC Do?
Mannatech, Incorporated operates as a health and wellness company worldwide. It develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management products. The company primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was founded in 1993 and is headquartered in Flower Mound, Texas. MANNATECH INC (MTEX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Alfredo Bala and employs approximately 250 people, headquartered in COPPELL, Texas. With a market capitalization of $12M, MTEX is one of the notable companies in the Healthcare sector.
MANNATECH INC (MTEX) Stock Rating — Reduce (April 2026)
As of April 2026, MANNATECH INC receives a Reduce rating with a composite score of 40.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.MTEX ranks #3,137 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, MANNATECH INC ranks #463 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
MTEX Stock Price and 52-Week Range
MANNATECH INC (MTEX) currently trades at $5.63. The stock lost $0.63 (10.0%) in the most recent trading session. The 52-week high for MTEX is $12.45, which means the stock is currently trading -54.8% from its annual peak. The 52-week low is $6.14, putting the stock -8.4% above its annual trough. Recent trading volume was 11K shares, suggesting relatively thin trading activity.
Is MTEX Overvalued or Undervalued? — Valuation Analysis
MANNATECH INC (MTEX) carries a value factor score of 77/100 in the Blank Capital model, suggesting the stock trades at a meaningful discount to its fundamental earning power. The trailing price-to-earnings ratio is 6.19x, compared to the Healthcare sector average of 23.63x — a discount of 74%. The price-to-book ratio stands at 1.71x, versus the sector average of 2.75x. The price-to-sales ratio is 0.10x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, MTEX trades at 16.08x EV/EBITDA, versus 6.34x for the sector.
Based on these multiples, MANNATECH INC appears attractively valued relative to both its sector peers and the broader market. Value-oriented investors may find the current entry point compelling, particularly if the company's fundamental quality metrics also score well.
MANNATECH INC Profitability — ROE, Margins, and Quality Score
MANNATECH INC (MTEX) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is -8.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -1.7% versus the sector average of -33.1%.
On a margin basis, MANNATECH INC reports gross margins of 75.5%, compared to 71.5% for the sector. The operating margin is 0.6% (sector: -66.1%). Net profit margin stands at -0.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -0.8% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
MTEX Debt, Balance Sheet, and Financial Health
MANNATECH INC has a debt-to-equity ratio of 42.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 1.13x, suggesting adequate working capital coverage. Total debt on the balance sheet is $3M. Cash and equivalents stand at $7M.
MTEX has a beta of 0.47, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for MANNATECH INC is 40/100, reflecting average volatility within the normal range for its sector.
MANNATECH INC Revenue and Earnings History — Quarterly Trend
In TTM 2026, MANNATECH INC reported revenue of $115M and earnings per share (EPS) of $1.01. Net income for the quarter was $-558,000. Gross margin was 75.5%. Operating income came in at $918,000.
In Q3 2025, MANNATECH INC reported revenue of $29M and earnings per share (EPS) of $1.01. Net income for the quarter was $2M. Gross margin was 76.4%. Revenue grew -8.1% year-over-year compared to Q3 2024. Operating income came in at $2M.
In Q1 2025, MANNATECH INC reported revenue of $27M and earnings per share (EPS) of $-0.80. Net income for the quarter was $-2M. Gross margin was 74.3%. Revenue grew -9.6% year-over-year compared to Q1 2024. Operating income came in at $-833,000.
In FY 2024, MANNATECH INC reported revenue of $118M and earnings per share (EPS) of $1.32. Net income for the quarter was $2M. Gross margin was 77.6%. Revenue grew -10.7% year-over-year compared to FY 2023. Operating income came in at $1M.
Over the past 8 quarters, MANNATECH INC has experienced revenue contraction from $132M to $115M. Investors analyzing MTEX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
MTEX Dividend Yield and Income Analysis
MANNATECH INC (MTEX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
MTEX Momentum and Technical Analysis Profile
MANNATECH INC (MTEX) has a momentum factor score of 18/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 34/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 18/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
MTEX vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, MANNATECH INC (MTEX) ranks #463 out of 838 stocks based on the Blank Capital composite score. This places MTEX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing MTEX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MTEX vs S&P 500 (SPY) comparison to assess how MANNATECH INC stacks up against the broader market across all factor dimensions.
MTEX Next Earnings Date
No upcoming earnings date has been announced for MANNATECH INC (MTEX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy MTEX? — Investment Thesis Summary
The quantitative profile for MANNATECH INC suggests caution. The value score of 77/100 suggests attractive pricing relative to fundamentals. Momentum is weak at 18/100, a headwind for near-term performance.
In summary, MANNATECH INC (MTEX) earns a Reduce rating with a composite score of 40.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MTEX stock.
Related Resources for MTEX Investors
Explore more research and tools: MTEX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MTEX head-to-head with peers: MTEX vs AZN, MTEX vs SLGL, MTEX vs VMD.